

## POINT-TO-POINT Answers to the reviewers

Dear Editor and reviewers,  
we sincerely thank for the opportunity to revise the manuscript according to suggestions and comments.

Each changes is underlined in the revised text in yellow.

Referee(s)' Comments to Author:

### 1° Reviewer

*This review of biosimilars is very timely. Reassuring data are presented.*

- 1 The paper is wordy. Reducing wordiness to use space more efficiently would be appreciated.*

**The text has been shortened and summarized, especially in paragraphs with trial characteristic descriptions.**

- 2 There could be greater use of tables to summarize (and reduce in length) the long, dry text that describes study result details.*

**Table 1 summarize all details of trials performed on CT-P13, it has been corrected and implemented.**

- 3 I think mention of the variation in innovator product would help reassure readers, too.*  
**This information has been added.**

### 2° Reviewer

*Thank you for the opportunity for reviewing. A comprehensive, well reasoned review, with adequate literature, easy to understand and informative.*

- 1 Some minor misspellings to be corrected in editorial process.*

**Some misspelling have been corrected**

*See no problems with this paper*

### 3° Reviewer

*This is a very thorough review of the post-marketing assessment of biosimilars in IBD. The conclusions are well supported by the data presented and well referenced.*

*Some of the lengthy descriptions of the outcomes of the various studies could be better summarised in tables.*

**The text has been shortened and summarized, especially in paragraphs with trial characteristic descriptions. Table 1 summarize all details of trial performed on CT-P13, it has been implemented.**